ࡱ> DFC #bjbjo>o> 4B T T4NN8dXt(PRRRRRR$e JvvPP8`3]).(<00 W: 8 8vv N n: 鶹ԭ (State name of College and Department) Consent Form for Research Title: (The project title) Principle Investigator: (faculty member in charge of research if it is a student project) Co-Investigators: (names of other faculty or students if appropriate) Supported (or funded by): . You are being asked to take part in a research study. This form has important information about the reason for the study and what you will do if you choose to be in this research study. Conflict of interest: A statement should be made regarding the relationship between the investigator and subject. For example: Your instructor who is also the person responsible for this research study is both interested in your learning as well as the conduct of this study. You have the right to discuss this study with another person who is not part of the research team before making your decision whether or not to be in the study. What is the reason for the study? You are being asked to take part in a research study. This form has important information about the reason for the study, what you will do, and the way we would like to use the information we obtain from you if you choose to participate in the research study. This study is being done because:. You are asked to take part in the study because:. Include an explanation of the study purpose. Include the number of subjects you intend to enroll. What will you do if you choose to be in the study? As a subject in this study you will be asked Your part in this study will last for .. and will involve.visits. Each visit will last x hours. Describe chronologically, the participants expected participation from the protocol. A chart is helpful if there are many visits. At any time in the study, you may decide to withdraw from the study. If you wish to withdraw no more information will be collected from you. What are some of the risks and discomforts that may happen to people who are in the study? Your participation in this study does not involve any emotional or physical risk to you beyond that of everyday life. OR Your participation does not involve any risks other than what you would encounter in daily life. OR your participation may include the following risks: Describe the possible risks include emotional, psychological, physical, financial, social risks that may be related to breach of privacy or confidentiality. You may withdraw from the study at any time. What are some of the potential benefits that are likely to come from my being in this study? You are not likely to have any direct benefit OR The possible benefits from being in this study are OR Taking part in this study may not benefit you but it may help obtain information to understand Explain how it might help understand the concept being studied. What other procedures or treatments might be available to me? You may choose to not participate in this research study. This section is used to describe treatment alternativesif not applicable then delete this category. How will my confidentiality be protected? Participation in this study may result in a loss of privacy, since persons other than the investigator might view your study records. Unless required by law, only the investigator, members of the investigators staff, representative of the (sponsor-if there is not one delete), the 鶹ԭ Institutional Review board, and representatives from the Office of Research Protections (OHRP) have authority to view your study records. They are required to maintain confidentiality regarding your identity. Describe provisions for confidentiality of subject and recordswho will maintain the records and for how long. Results of this research study may be used for teaching, other research, publications, or presentations at professional meetings. If your individual results are discussed, your identity will be protected by the use of a code number. No identifying information will be used. Are there any financial costs to being in the study? Participation will involve no cost to you. You will not be paid for participating in this study OR provide specific information about payment and reimbursement. Termination of participation by you or the Investigator If you wish to terminate your participation in this study at any time you may do so by contacting the investigator (by mail) .(provide the information needed to contact the investigator) If there are any circumstances which the investigator may terminate the subjects participation then describe it here i.e. lack of compliance etc. If this does not apply, delete this section. Audio/Video recording (if applicable) At the end of the consent form, you will be given the option of allowing the investigator to take pictures and/or make audio or video recordings. If you agree, these may be used in analyzing the research data or in scientific publications or presentations. With your permission, we may publish and present photographs, audio recordings, and videos of you (including/not including) your face. No other personal information about you will be included in the presentation. Use this if you have optional study elements such as photography, audio or videotaping. If one of these elements such as audiotaping is required for the study it would be included in the description of the study and would not have a separate consent here. Whom should I call if I have Questions or Concerns about this Research Study? If you have any questions, problems, illness, injury during your time on this study (alter if needed) call the investigator promptly. (PIs name) is in charge of this study. You can reach him/her at (phone number) during (insert time available) with questions about this research. You may also contact 鶹ԭs Institutional Review Board. If you wish further information regarding your rights as a research participant, you may contact the 鶹ԭ Institutional Review Board Administrator, Dr. William Chura, Associate Provost for Research and Faculty Development,  HYPERLINK "mailto:churawi@lewisu.edu" churawi@lewisu.edu or 815-836-5977. Optional Study Elements _____ (initial) I agree to. _____ (initial) I do not agree to. Consent (all components of the consent should be on one page) I have read this form and the research study has been explained to me. I have been given the opportunity to ask questions and my questions have been answered. If I have additional questions, I know have been told whom to contact. I agree to participate in the research study described above and will receive a copy of this form after I have signed it. _____________________________________ ___________ Subjects Name (printed) and Signature Date _______________________________________ ____________ Name (printed) and Signature of Person Obtaining Consent Date     Page  PAGE 2 of  NUMPAGES 4 78QRZ[lmnҼҧscTsB3hMhMCJOJQJaJ"hcU6B* CJOJQJaJphI}hcUhcUCJOJQJaJhcUB* CJOJQJaJphI}( *hhcUB* CJOJQJaJphI}%hcUhcUB* CJOJQJaJphI}h>CJOJQJaJ(hcUhcU6B* CJOJQJaJphI}+ *hhK-6B* CJOJQJaJphI}+ *hhcU6B* CJOJQJaJphI}hMCJOJQJaJhcUCJOJQJaJ8Sn -  I ~ ETU^gdcU$a$gdcU  & ) * , - X g ĸth\L\9\%hhB* CJOJQJaJphp *hhCJOJQJaJhCJOJQJaJh8]^CJOJQJaJhKXCJOJQJaJ%h8]^hcUB* CJOJQJaJphp( *hhB* CJOJQJaJphph8]^B* CJOJQJaJphph#\CJOJQJaJhcUCJOJQJaJhMhMCJOJQJaJ( *hhMB* CJOJQJaJphI}hMCJOJQJaJ   ~ wjZJZJ;hZh2CJOJQJaJ *hh2CJOJQJaJ *hh= CJOJQJaJhZ5CJOJQJaJhZhZ5CJOJQJaJ"hZ6B* CJOJQJaJphI}"hZ6B* CJOJQJaJphI}(hZhZ6B* CJOJQJaJphI}hZhZCJOJQJaJ *hhZCJOJQJaJhhKX5CJOJQJaJhhZ5CJOJQJaJ $CN]_ySTUIJًyj[NA4hZ5CJOJQJaJhX5CJOJQJaJhe5CJOJQJaJhheCJOJQJaJhZhZCJOJQJaJ"h8]^6B* CJOJQJaJphI}"h26B* CJOJQJaJphI}(h6hX6B* CJOJQJaJphI}"h66B* CJOJQJaJphI}(h6h66B* CJOJQJaJphI}"hZ6B* CJOJQJaJphI}(h6h26B* CJOJQJaJphI} ]^ιwhXK>X1h65CJOJQJaJh8]^5CJOJQJaJh9`5CJOJQJaJh6h65CJOJQJaJhJhJCJOJQJaJhJCJOJQJaJ"hX6B* CJOJQJaJphI}"hJ6B* CJOJQJaJphI}"hhJ6B* CJOJQJaJphI}(hXhX6B* CJOJQJaJphI}(hXh66B* CJOJQJaJphI}hZCJOJQJaJ *hhZCJOJQJaJNQRS012îÞp[K>1hJ5CJOJQJaJh65CJOJQJaJh6h65CJOJQJaJ(hJhJ6B* CJOJQJaJphp"hJ6B* CJOJQJaJphph6CJOJQJaJ *hh6CJOJQJaJ *hhJCJOJQJaJ( *hhJB* CJOJQJaJphI}+ *hhJ6B* CJOJQJaJphI}+ *hh66B* CJOJQJaJphI} *hh6CJOJQJaJR2lfyPG-S ! E !gdhJgdcU2klfwxy˹zkVzJ;+h6h65CJOJQJaJhkchkcCJOJQJaJhkcCJOJQJaJ(h6#\h9`6B*CJOJQJaJphThkcheCJOJQJaJ *hhkcCJOJQJaJ *hheCJOJQJaJh9`5CJOJQJaJ"h66B* CJOJQJaJphI}"hJ6B* CJOJQJaJphI}(h6h66B* CJOJQJaJphI}hJhJCJOJQJaJ *hhJCJOJQJaJOPowG,--Ӿn^N>(+ *hhF6B* CJOJQJaJphp *hhFCJOJQJaJ *hhkcCJOJQJaJhkchkc5CJOJQJaJ"hb6B* CJOJQJaJphp"hhJ6B* CJOJQJaJphphhJ5CJOJQJaJhb5CJOJQJaJ"hJ6B* CJOJQJaJphp(hJhJ6B* CJOJQJaJphphJhJCJOJQJaJ *hhJCJOJQJaJh65CJOJQJaJRS'(0Gl¶r\\G;hjECJOJQJaJ( *hhFB* CJOJQJaJphp+ *hhF6B* CJOJQJaJphp"hF6B* CJOJQJaJphp(hFhF6B* CJOJQJaJphphF5CJOJQJaJhFhF5CJOJQJaJhhJCJOJQJaJ(hjEhhJ6B* CJOJQJaJphphkcCJOJQJaJhFCJOJQJaJ *hhFCJOJQJaJQ  Ȼ׌wdWJ;hahaCJOJQJaJhs0$5CJOJQJaJhF5CJOJQJaJ%hkchjEB* CJOJQJaJphp(hjEhkc6B* CJOJQJaJphphKcIhFCJOJQJaJhAahAaB* OJQJphp!jhAahAa0JOJQJUhAahAa0JOJQJjhAahAaOJQJUhAahAaOJQJhKcIhKcICJOJQJaJhKcIhjECJOJQJaJ ! D E L M !J""""""""""""""##### ######ƹֆ~z~z~z~zvrkc_cVckc_cVckhz-mHnHuhjhU hhFh8mnh6#\h~hjhUhK-CJOJQJaJ"h26B* CJOJQJaJphp(haha6B* CJOJQJaJphpha5CJOJQJaJhaha5CJOJQJaJhaCJOJQJaJhahaCJOJQJaJhahFCJOJQJaJ!!!"J"""""""""""""#####$a$$a$gd~ dgd8mngdcU#####hK-CJOJQJaJhh+h8mn21h:pM/ =!"#$% j 666666666vvvvvvvvv666666>6666666666666666666666666666666666666666666666666hH6666666666666666666666666666666666666666666666666666666666666666662 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ OJPJQJ_HmH nH sH tH J`J MNormal dCJ_HaJmH sH tH DA D Default Paragraph FontRiR 0 Table Normal4 l4a (k ( 0No List >@> 8mn0HeaderdH$.. 8mn0 Header Char> @> 8mn0FooterdH$.!. 8mn0 Footer Char6U`16 e0 Hyperlink >*B*phR@BR Y0 Balloon Text dCJOJQJ^JaJNoQN Y0Balloon Text CharCJOJQJ^JaJPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] B 3336 2 ## !#X!-/6!L# @0(  B S  ?ORSUQLO8 ^`OJQJo( 8^8`OJQJo(^`OJQJ^Jo(o  p^ `OJQJo(  @ ^ `OJQJo( x^x`OJQJo(H^H`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(;(= hJbF!">Ts0$z- @zEKcIJ]MKXY6#\.]8]^Aa6h8mn$sI|MkchFXZZ`9`9M es+#\cUb[K-jEaP>bm6~[286@@UnknownG*Ax Times New Roman5Symbol3. *Cx Arial7.@Calibri5. .[`)Tahoma?= *Cx Courier New;WingdingsA$BCambria Math"1hxgxgG 0 0!02QHP  $PcU2!xx fitzgekagoyettsy Oh+'08x    (0 fitzgeka Normal.dotm goyettsy2Microsoft Office Word@@~)@v]@v]՜.+,D՜.+,< hp  鶹ԭ0   Title 8@ _PID_HLINKSAl{^mailto:churawi@lewisu.edu  !#$%&'()*+,-./012456789:<=>?@ABERoot Entry Fk]G1Table" WordDocument4BSummaryInformation(3DocumentSummaryInformation8;CompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q